This concept was taken further by utilizing an scFv targeting B7H6, a ligand for NKp30, to create a CAR that targets multiple tumor cells while demonstrating an impressive safety profile, since B7H6 is not constitutively expressed on healthy tissues (191). This evidence concerns the gene NCR3 and neoplasm.